CDK4 antibody (AA 150-303)

Catalog No. ABIN7870918

The Mouse Monoclonal anti-CDK4 antibody (Clone CDK4-8896) (ABIN7870918) specifically detects CDK4 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for CDK4 antibody (AA 150-303) (ABIN7870918)

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CDK4 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: CDK4-8896

Product Details anti-CDK4 Antibody

Binding Specificity: AA 150-303

Purpose: Cyclin-dependent kinase 4 Antibody / CDK4 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A recombinant fragment (within amino acids 150-303) of human Cyclin-dependent kinase 4 protein was used as the immunogen for the Cyclin-dependent kinase 4 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the Cyclin-dependent kinase 4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Aliquot the Cyclin-dependent kinase 4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CDK4

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Alternative Name: Cyclin-dependent kinase 4

Background: Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level (PMID:17253961). CCND1- CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth (PMID:21844184). CDK4 is highly expressed in highly differentiated and dedifferentiated liposarcomas, but rarely expressed in other benign liposarcomas and other sarcomas. CDK4 and MDM2 combined to differentiate between highly differentiated liposarcoma (+), dedifferentiated liposarcoma (+) and myxoid liposarcoma, pleomorphic liposarcoma, spindle lipoma, pleomorphic lipoma and other high-grade sarcomas.

UniProt: P11802

Pathways: Cell Division Cycle, Mitotic G1-G1/S Phases, Regulation of Cell Size